Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.
[canavan disease]
Recombinant
adeno-associated
virus
(
rAAV
)
vectors
mediating
long
term
transgene
expression
are
excellent
gene
therapy
tools
for
chronic
neurological
diseases
.
While
rAAV
2
was
the
first
serotype
tested
in
the
clinics
,
more
efficient
vectors
derived
from
the
rh
10
serotype
are
currently
being
evaluated
and
other
serotypes
are
likely
to
be
tested
in
the
near
future
.
In
addition
,
aside
from
the
currently
used
stereotaxy-guided
intraparenchymal
delivery
,
new
techniques
for
global
brain
transduction
(
by
intravenous
or
intra-cerebrospinal
injections
)
are
very
promising
.
Various
strategies
for
therapeutic
gene
delivery
to
the
central
nervous
system
have
been
explored
in
human
clinical
trials
in
the
past
decade
.
Canavan
disease
,
a
genetic
disease
caused
by
an
enzymatic
deficiency
,
was
the
first
to
be
approved
.
Three
gene
transfer
paradigms
for
Parkinson
's
disease
have
been
explored
:
converting
L-
dopa
into
dopamine
through
AADC
gene
delivery
in
the
putamen
;
synthesizing
GABA
through
GAD
gene
delivery
in
the
overactive
subthalamic
nucleus
and
providing
neurotrophic
support
through
neurturin
gene
delivery
in
the
nigro-striatal
pathway
.
These
pioneer
clinical
trials
demonstrated
the
safety
and
tolerability
of
rAAV
delivery
in
the
human
brain
at
moderate
doses
.
Therapeutic
effects
however
,
were
modest
,
emphasizing
the
need
for
higher
doses
of
the
therapeutic
transgene
product
which
could
be
achieved
using
more
efficient
vectors
or
expression
cassettes
.
This
will
require
re
-addressing
pharmacological
aspects
,
with
attention
to
which
cases
require
either
localized
and
cell-
type
specific
expression
or
efficient
brain
-
wide
transgene
expression
,
and
when
it
is
necessary
to
modulate
or
terminate
the
administration
of
transgene
product
.
The
ongoing
development
of
targeted
and
regulated
rAAV
vectors
is
described
.
Diseases
Validation
Diseases presenting
"been explored in human clinical trials in the past decade"
symptom
canavan disease
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom